retatrutide 2025 trial results CutKilo | The MariTide phase 2 trial

Immunosuppressive drug therapy and bone marrow transplants are another option

At 3 weeks follow-up, HR with liraglutide was significantly elevated compared with placebo (n = 17) for the whole 24-h period, day- and nighttime (least squares mean differences were 5.2, 4.6, and 7.3 bpm, respectively) [26]

Kline CE, et al

Incretins (GLPs/GIPs) are Helping Millions, but Additional Therapies are Needed By providing both glycemic control and significant weight loss, injectable incretin treatments (GLP-1s and GLPs/GIPs) are helping millions of individuals achieve their glycemia and weight loss targets

Wang X et al., 2019)

The HOPE Asia network 2022 up-date consensus statement on morning hypertension management